晚期胃癌二线化疗的预后因素分析

被引：3

作者：

赵荣荣 ^{[1
,2
]}

刘波 ^{[1
]}

韩淑梅 ^{[1
]}

张国栋 ^{[1
]}

牛作兴 ^{[1
]}

机构：

[1] 山东省肿瘤医院内四病区

[2] 济南大学·山东省医学科学院医学与生命科学学院

来源：

中华肿瘤防治杂志 | 2013年 / 20卷 / 14期

关键词：

晚期胃癌; 二线化疗; 预后; 多因素分析;

D O I：

10.16073/j.cnki.cjcpt.2013.14.017

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100214 ;

摘要：

目的:探讨晚期胃癌患者二线化疗的预后因素,筛选二线化疗的最佳人群。方法:回顾性分析256例接受二线化疗的晚期胃癌患者,采用Kaplan-Meier法计算生存率,Log-rank检验比较各亚组生存率,采用Cox比例分析模型作临床病理特征对生存率影响的单因素和多因素分析。结果:二线化疗的客观有效率18.0%,中位至进展时间(TTP)3.0个月,中位生存期(OS)8.1个月,1年生存率24.4%。多因素分析发现,分化程度(RR=1.33;95%CI:1.02～1.74;P=0.04)、一线化疗的TTP(RR=2.12;95%CI:1.59～2.83;P=0.00)、二线化疗前PS评分(RR=5.42;95%CI:3.65～8.05;P=0.00)和血红蛋白(RR=3.56;95%CI:2.49～5.09;P=0.00)是晚期胃癌二线化疗的独立预后因素。根据患者含预后不良因素的个数,分为低危(0)、中危(1～2)和高危(3～4)3组,3组的中位生存期分别为10.2、6.4和3.3个月,1年生存率分别为39.2%和8.5%,0,P=0.00。结论:影响晚期胃癌二线化疗的独立预后因素包括分化程度、二线化疗前PS评分、血红蛋白和一线化疗的TTP,可作为筛选晚期胃癌二线化疗适宜人群的有效指标。

引用

页码：1106 / 1109

页数：4

共 14 条

[1]

A retrospective analysis of sec-ond-line chemotherapy in patients with advanced gastric cancer. Ji SH,Lim do H,Yi SY,et al. BMC Cancer . 2009

[2]

Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer[J] . Yasushi Sato,Tetsuji Takayama,Tamotsu Sagawa,Yasuo Takahashi,Hiroyuki Ohnuma,Syunichi Okubo,Naoaki Shintani,Shingo Tanaka,Masaya Kida,Yasuhiro Sato,Hidetoshi Ohta,Koji Miyanishi,Tsutomu Sato,Rishu Takimoto,Masayoshi Kobune,Koji Yamaguchi,Koichi Hirata,Yoshiro Niitsu,Junji Kato. &nbspCancer Chemotherapy and Pharmacology . 2010 (4)

[3]

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)[J] . Peter C. Thuss-Patience,Albrecht Kretzschmar,Dmitry Bichev,Tillman Deist,Axel Hinke,Kirstin Breithaupt,Yasemin Dogan,Bernhard Gebauer,Guido Schumacher,Peter Reichardt. &nbspEuropean Journal of Cancer . 2011 (15)

[4]

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)[J] . Kei Muro,Narikazu Boku,Yasuhiro Shimada,Akihito Tsuji,Shinichi Sameshima,Hideo Baba,Taroh Satoh,Tadamichi Denda,Kenji Ina,Tomohiro Nishina,Kensei Yamaguchi,Hiroya Takiuchi,Taito Esaki,Shinya Tokunaga,Hiroyuki Kuwano,Yoshito Komatsu,Masahiko Watanabe,Ichinosuke Hyodo,Satoshi Morita,Ke

[5]

Aprognostic model in pa-tients treated for metastatic gastric cancer with second-linechemotherapy. Kanagavel D,Pokataev IA,Fedyanin MY. Annals of Oncology . 2010

[6]

Oncology[P]. 英国专利:GB9814580D0,1998-09-02

[7]

Feasibility study of trip-let combination chemotherapy of paclitaxel,cisplatin and S-1foradvanced gastric cancer. Fujitani K,Hasegawa H,Hirao M,et al. Anticancer Research . 2011

[8]

A phaseⅡstudy of irinotecan,continuous 5-fluorouracil,and leucoborin(FOLFIRI)combinationchemotherapy for patients with recurrent or metastatic gastriccancer previously treated with a fluoropyrimidine-based regimen. Kim SH,Lee GW,Go SI,et al. American Journal of Clinical Oncology . 2010

[9]

A phaseⅡstudy of irinote-can in combination with cisplatin as second-line chemotherapy inpatients with metastatic or locally advanced gastric cancer. Shen WC,Yang TS,Hsu HC,et al. Chang Gung Medical Journal . 2011

[10]

Randomized phaseⅢstudy comparing the efficacy and safety of irinotecan plus S-1a-lone as first-line treatment for advanced gastric cancer(studyGC0301/TOP-002). Narahara H,lishi H,Imamura H,et al. Gastric Cancer . 2011

← 1 2 →